Firing up the nature/nurture controversy: Bioethics and genetic determinism

Journal of Medical Ethics

Volumn 31, Issue 9, 2005, Pages 526-530

  de Melo Martin I ^a  

^a ST MARY'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E;

ALZHEIMER DISEASE; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BEHAVIOR; BREAST CANCER; CANCER RISK; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; GENETIC TRAIT; HEREDITY; HETEROZYGOSITY; HUMAN; HUMAN GENETICS; HUMAN RIGHTS; HUNTINGTON CHOREA; MEDICAL ETHICS; MEDICAL INFORMATICS; MORALITY; MUTATIONAL ANALYSIS; POLICY; PREDICTION; RISK ASSESSMENT; SOCIAL BELIEF; TAY SACHS DISEASE; TUMOR SUPPRESSOR GENE; WELLBEING;

ANALYTICAL APPROACH; BIOETHICS AND PROFESSIONAL ETHICS; GENETICS AND REPRODUCTION;

BIOETHICS; GENETIC DETERMINISM; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HUMANS; PHENOTYPE;

EID: 24944498905     PISSN: 03066800     EISSN: None     Source Type: Journal    
DOI: 10.1136/jme.2004.008417     Document Type: Article

References (56)

1. Oyama S. Ontogeny of information: developmental systems and evolution. Cambridge: Cambridge University Press, 1985:26-7.
2. Oyama S. Terms in tension: what do you do when all the good words are taken? In: Oyama, S, Griffiths P, Gray R, eds. Cycles of contingency. Cambridge: The MIT Press, 2001:177-93.
3. Griffiths P. The fearless vampire conservator. In: Rehmann-Sutter C, Neumann-Held E, eds. Genes in development. Rereading the molecular paradigm. Durham, NC: Duke University Press, (in press). Reprint available at http://philsci-archive.pitt.edu/archive/00000728/00/ Fearless_Vampire_Conservator.PDF (accessed 3 Dec 2004).
4. Kass L. The wisdom of repugnance. In: Pence G, ed. Flesh of my flesh. Lanham, MD: Rowman and Littlefield, 1998:13-37.
5. US National Bioethics Advisory Commission. Cloning human beings: report and Recommendations of the National Bioethics Advisory Commission. Rockville, MD: US National Bioethics Advisory Commission, 1997.
6. Verhey AD. Cloning: revisiting an old debate. Kennedy Inst Ethics J 1994;4:227-34.
7. Callahan D. Perspective on cloning: a threat to individual uniqueness. Los Angeles Times 1993 Nov 12:B7.
8. Juengst E. Can enhancement be distinguished from prevention in genetic medicine? J Med Philosophy 1997; 22:125-42.
9. Glover J. What sort of people should there be? New York: Penguin, 1984.
10. Rhodes R. Genetic links, family ties, and social bonds: rights and responsibilities in the face of genetic knowledge. J Med Philosophy 1998;23:10-30.
11. Robertson S, Savulescu J. Is there a case in favour of predictive genetic testing in young children? Bioethics 2001; 15:26-49.
12. Ross LF, Moon MR. Ethical issues on genetic testing of children. Arch Pediatr Adolesc Med 2000;154:873-9.
13. Buchanan A, Brock DW, Daniels N, et al. From chance to choice. Cambridge: Cambridge University Press, 2000:ch 6.
14. Cohen CB. Wrestling with the future: should we test children for adult-onset genetic conditions? Kennedy Inst Ethics J 1998;8:111-30.
15. Purdy L. Genetics and reproductive risk: can having children be immoral? In: Reproducing persons: issues in feminist bioethics. Ithaca, NY: Cornell University Press, 1996:39-49.
16. MacDonald ME, Gines S, Gusella JF, et al. Huntington's disease. Neuromolecular Med 2003;4:7-20.
17. Ho LW, Carmichael J, Swartz J, et al. The molecular biology of Huntington's disease. Psychol Med 2001; 31:3-14.
18. Davies S, Ramsden DB. Huntington's disease. Mol Pathol 2001;54:409-13.
19. Wellington CL, Brinkman RR, O'Kusky JR, et al. Toward understanding the molecular pathology of Huntington's disease. Brain Pathol 1997;7:979-1002.
20. Wexler A. Mapping fate. Berkeley, CA: University of California Press, 1996.
21. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72:971-83.
22. Holzmann C, Schmidt T, Thiel G, et al. Functional characterization of the human Huntington's disease gene promoter. Brain Res Mol Brain Res 2001;92:85-97.
23. Durr A, Dode C, Hahn V, et al. Diagnosis of "sporadic" Huntington's disease. J Neurol Sci 1995; 129:51-5.
24. Risch N. Molecular epidemiology of Tay Sachs disease. Adv Genet 2001;44:233-52.
25. Rozenberg R, Pereira LD. The frequency of Tay Sachs disease causing mutations in the Brazilian Jewish population justifies a carrier screening program. Sao Paulo Med J 2001;119:146-9.
26. Peleg L, Karpati M, Gazit E, et al. Mutations of the hexosaminidase A gene in Ashkenazi and non-Ashkenazi Jews. Biochem Med Metab Biol 1994;52:22-6.
27. Yamanaka S, Johnson ON, Norflus F, et al. Structure and expression of the mouse B-hexosaminidase genes, hexa and hexb. Genomics 1994;21:588-96.
28. Sutton VR. Tay Sachs disease screening and counseling families at risk for metabolic disease. Obstet Gynecol Clin North Am 2002;29:287-96.
29. Zinberg RE, Kornreich R, Edelmann L, et al. Prenatal genetic screening in the Ashkenazi Jewish population. Clin Perinatol 2001;28:367-82.
30. Petersen GM, Rotter JI, Cantor RM, et al. The Tay Sachs disease gene in North American Jewish populations: geographic variations and origins. Am J Hum Genet 1983;35:1258-69.
31. Cummings M. Human heredity. principles and issues [6th ed]. Pacific Grove, CA: Brooks/Cole, 2003:ch 5.
32. Wilkie A. Genetic prediction: what are the limits? Stud Hist Phil Biol & Biomed Sci 2001;32:619-33.
33. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000;405:847-56.
34. Dennis C. Epigenetics and disease: altered states. Nature 2003;421:686-9.
35. Vineis P, Schulte P, McMichael AJ. Misconceptions about the use of genetic tests in populations. Lancet 2001; 357:709-12.
36. Dipple KM, McCabe ER. Phenotypes of patients with "simple" Mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics. Am J Hum Genet 2000; 66:1729-35.
37. Mickle JE, Cutting GR. Genotype-phenotype relationships in cystic fibrosis. Med Clin North Am 2000;84:597-607.
38. Scriver CR, Waters PJ. Monogenetic traits are not simple. Lessons from phenylketonuria. Trends Genet 1999; 15:267-72.
39. Senior V, Marteau TM, Weinman J. Impact of genetic testing on causal models of heart disease and arthritis: an analogue study. Psychol Health 2000;14:1077-88.
40. Senior V, Marteau TM, Peters TJ. Will genetic testing for predisposition for disease result in fatalism? A qualitative study of parents' responses to neonatal screening for familial hypercholesterolaemia. Soc Sci Med 1999;48:1857-60.
41. Glannon W. Genes and future people. Boulder, CO: Westview, 2001.
42. Wachbroit R. The question not asked: the challenge of pleitropic genetic tests. Kennedy Inst Ethics J 1998; 8:131-44.
43. Khabele D, Runowicz CD. Genetic counseling test, and screening for breast and ovarian cancer: practical and social consideration. Curr Womens Health Rep 2002;2:163-9.
44. Coughlin MJ, Khoury SS, Steinberg KK. BRCA1 and BRCA2 gene mutations and risk of breast cancer: public health perspectives. Am J Prev Med 1999;16:91-8.
45. Weitzel JN. The current social, political, and medical role of genetic testing in familial breast and ovarian carcinomas. Curr Opin Obstet Gynecol 1999;11:65-70.
46. Garber J. A 40 year old woman with a strong family history of breast cancer. JAMA 1999;282:1953-60.
47. Hopper JL, Southey MC, Dite GS, et al. Population based estimate of the average age specific cumulative risk of breast cancer for a defined set of proteintruncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999;8:741-7.
48. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-89.
49. Collins FS. BRCA1 - lots of mutations, lots of dilemmas. N Engl J Med 1996;334:186-8.
50. Shadlen MF, McCormick WC, Larson EB. Research agenda for understanding Alzheimer disease in diverse populations: work group on cultural diversity, Alzheimer's association. Alzheimer Dis Assoc Disord 2002;16(suppl 2):96-100S.
51. Green RC. Risk assessment for Alzheimer's disease with genetic susceptibility testing: has the moment arrived? Alzheimer's Care Quarterly 2002;3:208-14.
52. Warwick Daw E, Payami H, Nemens EJ, et al. The number of trait loci in late onset Alzheimer's disease. Am J Hum Genet 2000;66:196-204.
53. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, gender and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA 1997; 278:1349-56.
54. Kahn J. Ethical issues in genetic testing for Alzheimer's disease. Geriatrics 1997;52(suppl 2):30-2S.
55. Post SG, Whitehouse PJ, Binstock RH, et al. The clinical introduction of genetic testing for Alzheimer's disease. JAMA 1997;277:832-6.
56. Bird TD, Levy-Lahad E, Poorkaj P, et al. Wide range in age of onset for chromosome 1 type familiar Alzheimer disease. Ann Neurol 1996;40:932-6.